Homepage - Ipsen Group

News

07 / 09 / 2017

Ipsen at ESMO 2017

We are excited to be participating in the 2017 ESMO congress in Madrid from the 8th until the 12th of September. Discover all activities Ipsen is organising and data we are sharing at this year’s congress.

Press releases

Learn more

19 / 09 / 2017

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatme...

18 / 09 / 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for th...

10 / 09 / 2017

Ipsen and Exelixis announce results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in ...

Twitter

@IpsenGroup That’s a wrap on #ESMO17. Ipsen is proud to be part of the knowledge sharing in oncology research . 2017 Sep, 12 16:01
@IpsenGroup RT @EFPIA: #WeWontRest until there is a future without #cancer @IpsenGroup #ESMO17 https://t.co/Mq4MkYsLdu https://t.co/wNDzdM4KEL 2017 Sep, 12 15:20
@IpsenGroup RT @EFPIA: #WeWontRest until renal cancer becomes a chronic disease @IpsenGroup https://t.co/Mq4MkYsLdu #ESMO17 https://t.co/TsJUdafclM 2017 Sep, 12 12:08
@IpsenGroup Thank you all for contributing to an incredible #ESMO17. We are heading home to continue our relentless investigat… https://t.co/Evrc7pRVt8 2017 Sep, 12 11:00

Executive Leadership Team

David Meek Executive Leadership Team

The Executive Leadership Team leads the Group business, in the areas of scientific, legal, financial, commercial and strategic matters.

Learn more

FACTS AND FIGURES 2016

Registration Document
Read
Download

Annual report 2016
Read
Download

RESEARCH & DEVELOPMENT

Our commitment is based on a strengthened partnership policy, a promising pipeline, two specialized technological platforms and three benchmark R&D centers across the globe.

Learn more